Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Healthcare professionals and public health authorities have a central role in discussing vaccination against COVID-19 with their patients.

13 Jun 2021

Has COVID-19 vaccine confidence dropped following the pause of Johnson & Johnson/Janssen?

A new study, which was conducted by Vishala Mishra and Joseph P. Dexter at Madras Medical College, Chennai, India, suggests that the infamous pause in the administration of the Johnson & Johnson (J&J)/Janssen COVID-19 vaccine, advised by the FDA, has left doubt about the veracity of vaccine safety claims. This is a development that may have engendered vaccine hesitancy in a segment of the population.

11 Jun 2021

Zoonotic and vector-borne emerging tropical diseases pose a constant threat

A recent article published in the journal Frontiers in Tropical Diseases assessed the threat of emerging zoonotic and vector-borne tropical diseases.

26 May 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Which biomarkers can help predict adverse outcomes in COVID-19?

A team of researchers has conducted a systematic review to identify laboratory factors that can predict the risk of severe and critical COVID-19 as well as associated mortality rates. The team – from institutions in India and the USA – recently published their findings in the Journal of Clinical Medicine Research.

24 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Study confirms rare blood clotting risk linked to ChAdOx1-S vaccine - benefits still outweigh risks

New research published in BMJ confirmed evidence of blood clotting finding a small risk after receiving one Oxford-AstraZeneca ChAdOx1-S severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

12 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

Emergency physicians use heparin alternative to treat vaccine-induced blood clot

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance.

5 May 2021

New NCCN patient guidelines on anemia and neutropenia published

The National Comprehensive Cancer Network announced today the publication of new NCCN Guidelines for Patients: Anemia and Neutropenia, Low Red and White Blood Cell Counts funded by the NCCN Foundation and endorsed by The Leukemia and Lymphoma Society (LLS).

3 May 2021

Despite all the talk, Covid vaccination does not infect people with shingles

Posts are showing up all over social media tying Covid-19 vaccinations to shingles and other painful skin disorders.

30 Apr 2021

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Last Friday, the Centers for Disease Control and Prevention and the U.S. Food & Drug Administration lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S.

29 Apr 2021

FDA, CDC lift recommended pause on the use of Janssen COVID-19 vaccine in the U.S.

Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.

23 Apr 2021

Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks

A recent study by researchers at the University of British Columbia (B.C.) shows that the benefits of continuing the COVID-19 vaccine of front-line workers with the AstraZeneca vaccine outweigh the increased risk of prothrombotic thrombocytopenia.

19 Apr 2021

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile.

6 Apr 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Coronavirus deranges the immune system in complex and deadly ways

There's a reason soldiers go through basic training before heading into combat: Without careful instruction, green recruits armed with powerful weapons could be as dangerous to one another as to the enemy.

4 Mar 2021